通讯作者: 俞静, jz5531@sina.com

DOI：10.12201/bmr.202607.00002

Analysis of the healing effectand safety of Guyuling capsules combined with teriparatide in the treatment of postmenopausal osteoporosis

• 摘要：探讨骨愈灵胶囊联合特立帕肽治疗绝经后骨质疏松症的疗效及安全性，分析其联合治疗的协同作用。方法：收集2019年12月至2024年1月在本院接受治疗的84例绝经后骨质疏松症患者的临床资料，进行回顾性分析，按治疗方式分为常规组和联合组，每组42例患者。常规组使用特立帕肽治疗，联合组使用骨愈灵胶囊联合特立帕肽治疗。对比两组骨密度、骨代谢指标、中医证候评分、疗效及安全性。结果：治疗后联合组骨密度腰椎L1～4（t/P=6.057/0.000）、全髋骨（t/P=2.389/0.019）比常规组显著升高（P<0.05）。联合组（骨密度腰椎L1～4：t/P=22.771/0.000、全髋骨：t/P=10.241/0.000）与常规组（骨密度腰椎L1～4：t/P=7.546/0.000、全髋骨：t/P=6.773/0.000）治疗后二者骨密度均比治疗前显著升高（P<0.05）。治疗后联合组骨钙素（BGP）（t/P=7.776/0.007）、型胶原交联C-末端肽（β-CTX）（t/P=9.555/0.000）比常规组显著降低（P<0.05）。联合组、常规组治疗后BGP（t/P=61.220/0.000、t/P=50.827/0.000）、β-CTX（t/P=44.508/0.000、t/P=18.433/0.000）均比治疗前显著降低（P<0.05）。治疗后，联合组的中医证候评分比常规组显著降低（t/P=4.993/0.000），联合组、常规组治疗后中医证候评分均比治疗前显著降低（t/P=21.584/0.000、t/P=16.285/0.000）。联合组疗效总有效率比常规组显著升高（χ2/P=4.941/0.026）。联合组与常规组不良反应的总发生率之间无显著差异（χ2/P=0.553/0.457）。结论：骨愈灵胶囊联合特立帕肽治疗绝经后骨质疏松症的疗效较好，可改善骨密度、骨代谢且安全性高。

  关键词： 绝经后骨质疏松症；骨愈灵胶囊；特立帕肽；疗效；安全性; ; ; ; 

   

  Abstract: To investigate the healing effect and safety of Guyuling capsules combined with teriparatide in the treatment of postmenopausal osteoporosis, and analyze the synergistic effect of their combined treatment.Methods: The clinical data of 84 cases of postmenopausal osteoporosis treated in our hospital from December 2019 to January 2024 were collected and analyzed retrospectively. According to the treatment methods, they were divided into routine group and combined group, with 42 patients in each group.The conventional group was treated with teriparatide, while the combined group was treated with Guyuling capsules in combination with teriparatide.The bone density, bone metabolism indicators, Chinese medicine syndrome scores, healing effect, and safety of the two groups were compared.Results: After treatment, the bone densities of lumbar vertebrae L1-4 （t/P=6.057/0.000）and total hip （t/P=2.389/0.019）in the combined group were obviously higher than those in the conventional group (P<0.05).After treatment, combined group and conventional group（lumbar vertebrae L1-4: t/P=22.771/0.000、total hip: t/P=10.241/0.000）showed a obvious increase in bone density compared to before treatment (P<0.05).After treatment, the combined group showed a obvious decrease in bone glaprotein(BGP) （t/P=7.776/0.007） and type I collagen carboxy-terminal peptide (β-CTX) （t/P=9.555/0.000） compared to the conventional group (P<0.05).After treatment, combined group and conventional group showed obvious reductions in BGP （t/P=61.220/0.000、t/P=50.827/0.000）and β-CTX （t/P=44.508/0.000、t/P=18.433/0.000）compared to before treatment (P<0.05).After treatment, the TCM syndrome scores of the combined group （t/P=4.993/0.000）were obviously lower than those of the conventional group (P<0.05), and combined group and conventional group （t/P=21.584/0.000、t/P=16.285/0.000）showed a obvious decrease in TCM syndrome scores after treatment compared to before treatment (P<0.05).The total effective rate of the combined group was obviously higher than that of the conventional group （χ2/P=4.941/0.026）.There was no obvious difference in the overall incidence of adverse reactions between the combined group and the conventional group （χ2/P=0.553/0.457）.Conclusion: The combination of Guyuling capsules and teriparatide has a good healing effect on postmenopausal osteoporosis. It can improve bone density, bone metabolism, and has high safety.

  Key words: postmenopausal osteoporosis; Guyuling capsules; teriparatide; healing effect; safety

  提交时间：2026-07-01

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 许峻川, 费琦. BFH-OST和OSTA对于绝经后妇女骨质疏松风险预测的对比性研究. 2024. doi: 10.12201/bmr.202407.00019

  张忠良, 费霖莉, 冷燕奎. 加味二至丸辅助改善肩袖损伤伴绝经后骨质疏松症患者术后疗效的临床研究. 2025. doi: 10.12201/bmr.202512.00073

  吴雅文, 高静媛, 彭倩倩, 刘敬未, 严涵, 杨雨旸. 老年人群骨质疏松症的研究进展. 2025. doi: 10.12201/bmr.202502.00044

  蔡小继, 车璇. 经阴道子宫切除术治疗绝经后非脱垂高级别宫颈病变的可行性和安全性. 2025. doi: 10.12201/bmr.202501.00068

  <p>马文萍. 丹参酮胶囊联合小剂量异维A酸软胶囊治疗痰湿瘀结型中重度痤疮效果及安全性 的回顾性队列研究. 2026. doi: 10.12201/bmr.202606.00063

  李森强, 冯琦, 宋才渊, 李伦辛. 张氏清热消瘀汤联合VSD治疗胫腓骨开放性骨折创面感染疗效及安全性. 2024. doi: 10.12201/bmr.202410.00023

  张颖, 王业流, 周淑萍. 艾司奥美拉唑联合荜铃胃痛颗粒治疗EPS的临床疗效与安全性研究. 2025. doi: 10.12201/bmr.202501.00052

  林坤山, 戢婷. 乌灵胶囊联合酒石酸唑吡坦片治疗失眠的疗效观察. 2025. doi: 10.12201/bmr.202507.00024

  沈群华, ▲ 於敏. 特发性矮身材患儿不同生长激素治疗方案的疗效及安全性. 2025. doi: 10.12201/bmr.202511.00012

  葛桑榆, 杨华娣, 李慧, 张晨, 毛佩瑜. 中药或中西药结合治疗子宫内膜异位症有效性及安全性的Meta分析. 2026. doi: 10.12201/bmr.202602.00053

• 序号	提交日期	编号	操作
  1	2026-05-20	10.12201/bmr.202607.00002V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论